Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Rezolute ( (RZLT) ) just unveiled an update.
On January 10, 2025, Rezolute released a video showcasing a patient’s experience with their Phase 2 clinical study for the drug ersodetug, which is being explored as a treatment for hyperinsulinism. The patient, Paula, experienced improved quality of life and fewer hypoglycemic episodes while participating in the study. Rezolute is hopeful that ersodetug, now in a global Phase 3 trial, could significantly benefit many living with hyperinsulinism, although results for other patients may vary.
More about Rezolute
Rezolute, Inc. operates in the biopharmaceutical industry focusing on the development of innovative therapies, particularly targeting rare metabolic diseases. The company is currently advancing its investigational drug candidate, ersodetug, aimed at treating hyperinsulinism, a condition characterized by excessive insulin production leading to hypoglycemia.
YTD Price Performance: -7.77%
Average Trading Volume: 403,572
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $283.9M
Find detailed analytics on RZLT stock on TipRanks’ Stock Analysis page.
